Results 231 to 240 of about 219,778 (281)

Application of PI3K inhibitors in breast cancer treatment: a clinical trial landscape analysis based on clinical trial databases and registries. [PDF]

Front Oncol
Cao J, Chen Y, Song J, Li S, Tang Y, Zhang X, Zhang L, Ma L.   +7 more
europepmc   +1 more source

Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials. [PDF]

Front Pharmacol
Wali AF, Talath S, Babiker R, El-Tanani M, Rangraze IR, Ibraheem W, Al Aldhaheri Y, Satyam SM, El-Tanani Y.   +8 more
europepmc   +1 more source

Functionalized nanomedicines for co-targeting of multiple pathways to efficiently treat thyroid cancer: prospects and challenges. [PDF]

Front Pharmacol
Chu H, Wang D.
europepmc   +1 more source

Itraconazole in the Treatment of Aberrantly Active Hedgehog and/or PI3K Recurrent Ovarian Cancer. [PDF]

Cancers (Basel)
Hendrikse CSE, Voeten N, van der Ploeg P, Smedts HPM, Westgeest HM, Bosch S, Lalisang RI, Vriens BEPJ, Thijs AMJ, Lambrechts S, Bekkers RLM, Piek JMJ.   +11 more
europepmc   +1 more source

Translational insights into miR-126 and miR-423: biomarkers and therapeutic targets in cancer, cardiovascular, metabolic and kidney diseases. [PDF]

Front Mol Biosci
Rodzoń-Norwicz M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents

Current Opinion in Pharmacology, 2003
The phosphoinositide 3-kinase (PI3K) family of enzymes consists of several closely related isoforms that are thought to have distinct biological roles. Until now, researchers have been frustrated by poor selectivity of the available pharmacological inhibitors, which are unable to distinguish adequately the activities of different PI3K isoforms ...
Stephen G Ward, Peter Finan
exaly   +4 more sources

Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform

Journal of Medicinal Chemistry, 2011
Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3Kα has justly received the most attention for its potential in cancer therapy. Herein we report our successful approaches to achieve PI3Kα vs PI3Kβ selectivity for two chemical series.
Timothy P Heffron, Binqing Wei, Steven T Staben   +2 more
exaly   +4 more sources

Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.

Bioorganic & Medicinal Chemistry, 2004
Phosphoinositide 3-kinases (PI3-Ks) are an ubiquitous class of signaling enzymes that regulate diverse cellular processes including growth, differentiation, and motility. Physiological roles of PI3-Ks have traditionally been assigned using two pharmacological inhibitors, LY294002 and wortmannin. Although these compounds are broadly specific for the PI3-
Zachary A. Knight, G. Chiang, Peter J. Alaimo, Denise M. Kenski, Caroline B. Ho, Kristin Coan, R. Abraham, K. Shokat   +7 more
semanticscholar   +3 more sources

Therapeutic potential of phosphoinositide 3-kinase inhibitors

Expert Opinion on Therapeutic Patents, 2004
Originally discovered as oncogene-associated lipid kinases more than 15 years ago, the family of phosphoinositide 3-kinase (PI 3-K) enzymes has recently emerged as an important therapeutic target in human pathophysiology. After more than a decade with only a few inhibitors with low activity, poor isoform or kinase selectivity or unacceptable ...
B. Drees, G. Mills, C. Rommel, G. Prestwich   +3 more
semanticscholar   +2 more sources

Development of first lead structures for phosphoinositide 3-kinase-C2γ inhibitors.

Journal of Medicinal Chemistry, 2015
The importance of complete elucidation of the biological functions of phosphoinositide 3-kinases (PI3K) was realized years ago. They generate 3-phosphoinositides, which are known to function as important second messengers in many inter- and intracellular signaling pathways. However, the functional role of class II PI3Ks is still unclear.
A. Freitag, Prajwal Prajwal, A. Shymanets, C. Harteneck, B. Nürnberg, C. Schächtele, M. Kubbutat, F. Totzke, S. Laufer   +8 more
semanticscholar   +3 more sources